Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
Open Access
- 28 April 2022
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (6) , 2932-2945
Abstract
Introduction This study characterized real-world demographic and baseline clinical characteristics, as well as treatment persistence and adherence, in patients with psoriatic arthritis (PsA) who had newly initiated tofacitinib treatment. Methods This retrospective cohort study included patients aged 18 years or older in the IBM MarketScan™ US database with at least one tofacitinib claim (first = index) between December 14, 2017 and April 30, 2019; PsA diagnoses on/within 12 months pre-index; and no diagnoses of rheumatoid arthritis any time pre-index. Patients were continuously enrolled for 12 months pre-index and 6 months post-index, with no pre-index claims for tofacitinib. Patient demographic and clinical characteristics on the day of index, and history of advanced treatments (including tofacitinib monotherapy or combination therapy), were recorded. Outcomes at 6 months post-index included tofacitinib persistence (less than 60-day gap without tofacitinib treatment) and adherence (proportion of days covered [PDC] and medication possession ratio 80% or higher). Results Of the 10,354 patients with tofacitinib claims within the study period, 318 patients with PsA met the inclusion criteria. More than 60% of patients received tofacitinib monotherapy post-index, with a mean duration of PsA of 760.5 days at index. For patients who received tofacitinib combination therapy post-index, methotrexate was the most common concomitant conventional synthetic disease-modifying antirheumatic drug. At 6 months post-index, persistence was similar in patients receiving tofacitinib monotherapy (69.8%) versus combination therapy (73.1%); adherence (as measured by PDC ≥ 0.8) was numerically lower in patients receiving tofacitinib monotherapy (56.8%) versus combination therapy (65.5%). Conclusions This analysis of US-based claims data described patients who had newly initiated tofacitinib treatment an average of 2 years after PsA diagnosis, with approximately two-thirds of patients receiving tofacitinib monotherapy. Observed rates of tofacitinib persistence were similar across patients who received tofacitinib monotherapy and combination therapy 6 months after initiation; adherence rates were numerically lower in patients receiving monotherapy. Graphical AbstractKeywords
Funding Information
- Pfizer Inc
This publication has 29 references indexed in Scilit:
- The pathogenesis of psoriatic arthritisThe Lancet, 2018
- Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical RecordsJournal of Korean Medical Science, 2018
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF InhibitorsNew England Journal of Medicine, 2017
- Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisNew England Journal of Medicine, 2017
- Psoriatic ArthritisNew England Journal of Medicine, 2017
- The Epidemiology of Psoriatic ArthritisRheumatic Disease Clinics of North America, 2015
- Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysisJournal of the American Academy of Dermatology, 2015
- Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingJournal of Dermatological Treatment, 2013
- The burden of psoriatic arthritis: a literature review from a global health systems perspective.2010
- Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspectiveJournal of the American Academy of Dermatology, 2006